To include your compound in the COVID-19 Resource Center, submit it here.

Medigene sells U.S. rights for Veregen

Cancer immunotherapy company Medigene AG (Xetra:MDG1) granted

Read the full 71 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE